Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2024-05-07 Investor Presentation
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于举行2023年度网上业绩说明会暨参加厦门辖区上市公司投资者网上集体接待日活动的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling and details of a 2023 annual performance explanation meeting (业绩说明会) and participation in an investor online reception day. It mentions the date, format, attendees, and how investors can submit questions. The document does not contain actual financial data or detailed financial statements but rather informs about an upcoming event where such information will be discussed. The document length is short (830 characters), and it serves as a notice or announcement rather than the report itself. Therefore, it fits best into the category of Investor Presentation (IP) since it relates to a detailed presentation for investors focusing on financials, strategy, and market position, or possibly AGM Information (AGM-R) if it were an AGM. However, since it is specifically about a performance explanation meeting and investor interaction, Investor Presentation (IP) is the most appropriate classification.
2024-05-07 Chinese
关于回购股份进展的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from a company regarding the progress of its share repurchase program. It details the number of shares repurchased, prices, total amount spent, compliance with regulatory guidelines, and future plans for the buyback. There are no financial statements or comprehensive financial data presented, nor is this a report or presentation. The content fits the description of a Transaction in Own Shares (POS) filing, which reports on the company's buyback activities.
2024-05-07 Chinese
第三届监事会第十七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board regarding the approval of the company's 2024 first quarter report. It states that the Supervisory Board reviewed and approved the 2024 Q1 report, confirming its compliance with laws and regulations and the accuracy of its content. The document itself does not contain the full quarterly report or detailed financial statements but is an announcement of the Supervisory Board's approval of that report. The document length is short (620 characters), and it serves as a formal announcement of the meeting resolution rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement related to the quarterly report approval, not the quarterly report (IR) itself.
2024-04-22 Chinese
第三届董事会第十八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a board meeting resolution announcement from Xiamen Aide Biomedical Technology Co., Ltd. It reports the approval of the 2024 Q1 report by the board of directors, including voting results and meeting details. The actual quarterly report content is not included but referenced as available on the official disclosure website. The document length is short (608 characters) and serves as an announcement of the board meeting decision rather than the full quarterly report itself. Therefore, it is not the Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) announcing the board resolution and referencing the report.
2024-04-22 Chinese
2024年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "厦门艾德生物医药科技股份有限公司 2024 年第一季度报告" which translates to "Xiamen Aide Biomedical Technology Co., Ltd. 2024 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and shareholder information for the first quarter of 2024. The document explicitly states it is a quarterly report and mentions that it is unaudited. The length of the document (over 13,000 characters) and the presence of comprehensive financial statements confirm it is a substantive financial report for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2024-04-22 Chinese
2023年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2023年度监事会工作报告" which translates to "2023 Supervisory Board Work Report". It details the supervisory board's activities, meetings, oversight on company operations, financial management, internal controls, related party transactions, and information disclosure for the year 2023. The content is a formal report from the supervisory board summarizing their work and oversight for the year. It is not an annual report (10-K) or audit report (AR) but a specific supervisory board report. Given the nature of the document as a formal report from the supervisory board on their work and oversight, it fits best under the category of Management Reports (MDA), which includes management's detailed explanation of financial results, business trends, and outlook. The document is not a short announcement or certification, so it is not RPA or RNS. Therefore, the classification is MDA with high confidence.
2024-04-15 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.